<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895982</url>
  </required_header>
  <id_info>
    <org_study_id>C4591024</org_study_id>
    <secondary_id>2021-001290-23</secondary_id>
    <nct_id>NCT04895982</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability &amp; Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years</brief_title>
  <official_title>A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3 dose study with 420 participants (240 adults, 180 children). Participants are&#xD;
      going to be enrolled based on conditions that make them immunocompromised, Participants are&#xD;
      going to be followed up for 6 months after dose 3, and each participant is projected to be on&#xD;
      the study for 14 months, This study will be conducted in the United States, Brazil and&#xD;
      Germany&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">March 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants reporting local reactions</measure>
    <time_frame>For 7 days after Dose 1, Dose 2 and Dose 3</time_frame>
    <description>Pain at the injection site, redness and swelling, as self reported in electronic diaries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting systemic events</measure>
    <time_frame>For 7 days after Dose 1, Dose 2 and Dose 3</time_frame>
    <description>Fever, Fatigue, Headache, Chills, Vomiting, Diarrhoea, New or Worsened Muscle Pain, New or Worsened Joint Pain, as self reported in electronic diaries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting adverse events</measure>
    <time_frame>From Dose 1 through 1 month after Dose 2</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting serious adverse events</measure>
    <time_frame>From Dose 1 through 6 months after Dose 3</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMTs of all participants, measured by SARS-CoV-2 neutralising titers, without serological or virological evidence of past SARS-CoV-2 infection and with an immunocompromised state, as specified in the protocol</measure>
    <time_frame>1 month after Dose 2</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting adverse events</measure>
    <time_frame>From Dose 3 to 1 month after Dose 3</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>SARS-CoV-2 Infection, COVID19</condition>
  <arm_group>
    <arm_group_label>BNT162b2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2</intervention_name>
    <description>Intramuscular Injection</description>
    <arm_group_label>BNT162b2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Male or female participants who are ≥2 years of age at the time of enrollment&#xD;
             (Visit 1).&#xD;
&#xD;
             2. Participants or participants' parent(s)/legal guardians, as age appropriate, who&#xD;
             sign consent, and are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
             3. Life expectancy ≥12 months (365 days) in the opinion of the investigator at&#xD;
             enrollment (Visit 1).&#xD;
&#xD;
             4. Participants or participant's parent(s)/legal guardians, as age appropriate, who&#xD;
             are able to be contacted by telephone throughout the study period.&#xD;
&#xD;
             5. Female participant of childbearing potential or male participant able to father&#xD;
             children who is willing to use a highly effective method of contraception as outlined&#xD;
             in this protocol for at least 28 days after the last dose of study intervention if at&#xD;
             risk of pregnancy with her/his partner; or female participant not of childbearing&#xD;
             potential or male participant not able to father children.&#xD;
&#xD;
             6. Participants who are immunocompromised by virtue of the following:&#xD;
&#xD;
               -  Having known NSCLC and is ≥18 years of age with at least 1 of the following:&#xD;
&#xD;
               -  Who received chemotherapy at least 2 weeks (14 days) before enrollment (or is&#xD;
                  treatment naïve), and is not expected to receive chemotherapy within at least 2&#xD;
                  weeks (14 days) after dose administration; and/or&#xD;
&#xD;
               -  Receiving checkpoint inhibitor treatment (PD-1/PD-L1 inhibitor, CTLA-4 inhibitor)&#xD;
                  and has undergone at least 1 treatment cycle prior to enrollment (at Visit 1); or&#xD;
&#xD;
               -  Receiving targeted drug therapy treatment (EGFR, ALK, ROS1, BRAF, RET, MET, NTRK&#xD;
                  inhibitors) and has undergone at least 1 treatment cycle prior to enrollment (at&#xD;
                  Visit 1); or&#xD;
&#xD;
               -  Having known CLL and is ≥18 years of age with at least 1 of the following:&#xD;
&#xD;
               -  Has asymptomatic disease (eg, Rai stage &lt;3, Binet stage A or B) and is undergoing&#xD;
                  observation and does not receive any treatment for CLL; or&#xD;
&#xD;
               -  Receiving B-cell inhibitory monoclonal antibody treatment (anti-CD20) and has&#xD;
                  received at least 3 cycles prior to enrollment; and/or&#xD;
&#xD;
               -  Receives a BTK inhibitor, PI3K inhibitor, or BCL-2 inhibitor OR&#xD;
&#xD;
               -  Is currently undergoing maintenance hemodialysis treatment secondary to end-stage&#xD;
                  renal disease and is ≥18 years of age OR&#xD;
&#xD;
               -  Is on active immunomodulator therapy (eg, TNFα inhibitor, or tofacitinib or&#xD;
                  methotrexate) for an autoimmune or inflammatory disease disorder (eg,&#xD;
                  inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, and&#xD;
                  juvenile idiopathic arthritis, and inflammatory bowel disease, such as ulcerative&#xD;
                  colitis and Crohn's disease) at a stable* dose&#xD;
&#xD;
                    -  Stable dose is defined as receiving the same dose for at least 3 months (84&#xD;
                       days) with no changes in the 28 days prior to Visit 1.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Receiving a solid organ transplant at least 3 months (84 days) prior to enrollment&#xD;
             (Visit 1) and with no acute rejection episodes within 2 months (60 days) prior to&#xD;
             enrollment (Visit 1), and is ≥2 to &lt;18 years of age OR&#xD;
&#xD;
          -  Has had an autologous or allogenic bone marrow or stem cell transplant at least 6&#xD;
             months (182 days) prior to enrollment (Visit 1), with adequate immune reconstitution&#xD;
             for immunization, in the investigator's opinion, and is ≥2 to &lt;18 years of age 7. The&#xD;
             participant or participant's parent(s)/legal guardian is capable of giving signed&#xD;
             informed consent, and assent (as appropriate), as described in Appendix 1, which&#xD;
             includes compliance with the requirements and restrictions listed in the ICD and in&#xD;
             this protocol. The investigator, or a person designated by the investigator, will&#xD;
             obtain written informed consent (and assent, as appropriate) from each study&#xD;
             participant or participant's parent(s)/legal guardian (as defined in Appendix 1)&#xD;
             before any study-specific activity is performed. All parent(s)/legal guardians should&#xD;
             be fully informed, and participants should be informed to the fullest extent possible,&#xD;
             about the study in language and terms they are able to understand. The investigator&#xD;
             will retain the original copy of each participant's signed consent (and assent, as&#xD;
             appropriate) document(s).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Past clinical (based on COVID-19 symptoms/signs alone, if a SARS CoV 2 NAAT result&#xD;
             was not available) or microbiological (based on COVID-19 symptoms/signs and a positive&#xD;
             SARS-CoV-2 NAAT result) diagnosis of COVID 19, or a past clinical diagnosis of MIS-C.&#xD;
&#xD;
             2. Participants with active GVHD, transplant rejection, or PTLD, or participants who&#xD;
             have had treatment for these conditions within 3 months (84 days) prior to study&#xD;
             enrollment (Visit 1).&#xD;
&#xD;
             3. Participants &lt;18 years of age whose weight is less than the 5th percentile of&#xD;
             age-adjusted ideal body weight.&#xD;
&#xD;
             4. Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             of study participation or, in the investigator's judgment, make the participant&#xD;
             inappropriate for the study.&#xD;
&#xD;
             5. History of severe adverse reaction associated with a vaccine and/or severe allergic&#xD;
             reaction (eg, anaphylaxis) to any component of the study intervention(s).&#xD;
&#xD;
             6. Bleeding diathesis or condition associated with prolonged bleeding that would, in&#xD;
             the opinion of the investigator, contraindicate intramuscular injection.&#xD;
&#xD;
             7. Participant who is pregnant or breastfeeding. 8. Participants who may be ineligible&#xD;
             because of the number of phlebotomy assessments during this study, in the opinion of&#xD;
             the investigator.&#xD;
&#xD;
             9. Participants who do not have adequate deltoid muscle mass to allow intramuscular&#xD;
             vaccination, in the opinion of the investigator.&#xD;
&#xD;
             10. Previous vaccination with any coronavirus vaccine. 11. Ongoing, or history of,&#xD;
             treatment with blood/plasma products or immunoglobulins within 3 months (84 days)&#xD;
             prior to Dose 1 or planned receipt of these medications prior to Dose 3.&#xD;
&#xD;
             12. Participation in other studies involving study intervention within 28 days prior&#xD;
             to study entry and/or during study participation.&#xD;
&#xD;
             13. Previous participation in other studies involving study intervention containing&#xD;
             LNPs.&#xD;
&#xD;
             14. Participants who are direct descendants (child or grandchild, parent or&#xD;
             grandparent) of investigational site staff members or Pfizer/BioNTech employees&#xD;
             directly involved in the conduct of the study, site staff otherwise supervised by the&#xD;
             investigator, and their respective family members.&#xD;
&#xD;
             15. Investigator site staff or Pfizer employees directly involved in the conduct of&#xD;
             the study, site staff otherwise supervised by the investigator, and their respective&#xD;
             family members.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Comer Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>Jefferson</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center - Jefferson Highway</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital - Research Pharmacy</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute: Building Cure</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Obras Sociais Irma Dulce</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40.415-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade regional de Medicina de São José do Rio Preto</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SAO Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GRAACC - Grupo de Apoio ao Adolescente e à Criança com Câncer</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEPIC - Centro Paulista de Investigação Clínica</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co KG</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20359</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4591024</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Vaccine</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>RNA Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

